Investment Thesis
Cardiff Oncology is a pre-revenue biotech company with virtually no commercial traction ($41K quarterly revenue) and severe cash burn ($12.3M annually) against a limited cash position of $8.5M, implying less than 1 year of runway at current burn rate. Despite a debt-free balance sheet and strong liquidity ratios, the company faces imminent funding requirements or operational restructuring, creating significant dilution risk to shareholders.
Strengths
- Zero long-term debt and no leverage provides balance sheet flexibility
- Strong liquidity position with 3.27x current/quick ratios provides near-term operational cushion
- Positive stockholders' equity of $34.7M provides shareholder protection relative to liabilities
- Minimal capital expenditure requirements suggest asset-light development model
Risks
- Critically low cash runway of approximately 8 months at current $12.3M annual operating burn rate
- Virtually non-existent revenue generation ($41K annually) indicates zero commercial viability
- Declining revenue trajectory (-13.2% YoY) suggests worsening commercial position
- Imminent capital raise needed will likely result in significant shareholder dilution
- Binary outcome inherent to preclinical/clinical stage biotech with no validated pipeline asset generating revenue
- Operating losses of $12.3M against minimal asset base unsustainable without external funding
Key Metrics to Watch
- Cash runway and quarterly burn rate trends
- Pipeline milestone achievement and clinical trial progress
- Capital raise activity and terms (dilution percentage)
- Revenue inflection and partnership/licensing deals
Financial Metrics
Revenue
41.0K
Net Income
-12.3M
EPS (Diluted)
$-0.18
Free Cash Flow
-12.3M
Total Assets
49.2M
Cash
8.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-31,341.5%
Net Margin
-30,109.8%
ROE
-35.6%
ROA
-25.1%
FCF Margin
-30,078.0%
Balance Sheet & Liquidity
Current Ratio
3.27x
Quick Ratio
3.27x
Debt/Equity
0.00x
Debt/Assets
29.4%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:56:03.121796 |
Data as of: 2026-03-31 |
Powered by Claude AI